Navigation Links
Provectus Pharmaceuticals, Inc.'s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, today announced that its May 3rd RetailInvestorConferences.com presentation is now available for on-demand viewing.

LINK: www.retailinvestorconferences.com > red "register/ watch event now" button

Provectus Pharmaceuticals, Inc's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Provectus Pharmaceuticals Inc.

Provectus Pharmaceuticals (PVCT) specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.


'/>"/>
SOURCE Provectus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
2. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
3. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
4. Avion Pharmaceuticals, LLC Names Michael Sullivan as new VP, Sales and Marketing
5. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
6. Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™
7. Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
8. Gamma Pharmaceuticals, Inc. Announces Key Appointment in Sales and Marketing
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
11. Tibet Pharmaceuticals, Inc. Announces Intent to Go Private
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2020)... , ... February 20, 2020 , ... Enquire, a leading ... and post-acute care, is proud to announce G5 as a Silver Sponsor of Enquire ... “G5 is proud to return to Enquire Summit as a Silver Sponsor. This event ...
(Date:2/19/2020)... ... February 19, 2020 , ... Aspire Regenerative, a leader in offering therapies that ... for a free weight-loss event on March 1, 2020. It will take place from ... CA, 92037. , During the event, physicians and pharmacists will lead an informative and ...
(Date:2/19/2020)... Calif. (PRWEB) , ... February ... ... electronic lab notebook platform for research data management, has released a new ... powerful research data management features. With a ‘Quick View’ of supported DNA ...
Breaking Medicine Technology:
(Date:2/20/2020)... ... February 20, 2020 , ... R3 Stem Cell, the nation's ... to complete 70 complimentary stem cell procedures on military veterans in 2019. ... no cost. , At the R3 Stem Cell Training Course for doctors , providers ...
(Date:2/19/2020)... MONROE, Conn. (PRWEB) , ... February 19, 2020 ... ... respected periodontists at Advanced Periodontics and Dental Implant Center of Connecticut, celebrate 30 ... all new patients with the same low fees that they charged in 1989, ...
(Date:2/19/2020)... ... February 19, 2020 , ... In ... scope of regulations and requirements that currently govern medical device manufacturers under the ... extends until 25 May 2020. Major changes from the previous MDD include:, ...
(Date:2/19/2020)... ... February 19, 2020 , ... SafiraMD Medical Aesthetics & Wellness ... the world’s most popular non-invasive fat reduction treatment. Their CoolEvent will be held ... Center in Alpharetta, Georgia. The CoolEvent will feature live demonstrations, exclusive discounts, giveaways ...
(Date:2/15/2020)... ... February 14, 2020 , ... Sister companies, Special Learning ... “BIG MONEY IN ABA”. The series explores the challenges, risks, and opportunities of ... the series on March 25, 2020 at: https://bit.ly/2OU6lxg , Since 2010, ...
Breaking Medicine News(10 mins):